MapLight Therapeutics Completes Enrollment for Two Phase 2 Trials, Reports Q1 Results

summarizeSummary

MapLight Therapeutics announced the completion of enrollment for its Phase 2 ZEPHYR and IRIS trials, with topline results anticipated by mid-August 2026, alongside Q1 2026 financial results and a reaffirmed cash runway through 2027.

check_boxKey Events

• Phase 2 Enrollment Completed

  Enrollment has been completed for ML-007C-MA's Phase 2 ZEPHYR trial in schizophrenia (307 participants) and ML-004's Phase 2 IRIS trial in autism spectrum disorder (161 participants).

• Upcoming Topline Results

  Topline results for both the ZEPHYR and IRIS trials are expected by mid-August 2026, representing significant near-term catalysts.

• Q1 2026 Financials Reported

  The company reported a net loss of $60.7 million for the first quarter of 2026, an increase from $22.3 million in Q1 2025, with R&D expenses rising to $53.7 million.

• Cash Runway Extended Through 2027

  MapLight Therapeutics ended Q1 2026 with $395.2 million in cash, cash equivalents, and investments, which is expected to fund operations through 2027.

auto_awesomeAnalysis

This 8-K highlights significant clinical progress for MapLight Therapeutics, with the completion of enrollment for two key Phase 2 trials (ZEPHYR for schizophrenia and IRIS for autism spectrum disorder). Topline results for both are expected by mid-August 2026, representing major near-term catalysts for the company. While the company reported an increased net loss for Q1 2026, its cash position of $395.2 million is expected to fund operations through 2027, providing a stable financial runway ahead of these critical data readouts.